Drug intelligence / Profile preview

HBIG + GM-CSF + HBV vaccine

Development stage: Unknown
Lead developer: The Fifth Medical Center of the PLA General Hospital
Modality: Cytokines & Interferons → Recombinant Proteins and Enzymes, Vaccines & Immunotherapeutics
Administration: Intramuscular, Subcutaneous

Overview

This combination immunotherapy regimen is being evaluated by Beijing 302 Hospital for the treatment of chronic hepatitis B (CHB). The regimen consists of Hepatitis B Immune Globulin (HBIG), Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF), and a Hepatitis B vaccine, administered in conjunction with standard nucleoside analogue therapy. The therapeutic strategy aims to overcome immune exhaustion and achieve HBsAg seroconversion in patients who have already achieved HBeAg seroconversion. HBIG is used to neutralize circulating HBsAg, while GM-CSF acts as an adjuvant to enhance dendritic cell function and antigen presentation. The HBV vaccine is intended to stimulate a de novo HBV-specific immune response. This multi-component approach is designed to restore host immunity and improve the clinical outcome of chronic HBV infection.

Other names: HBIG+GM-CSF+HBV vaccineHBIG + GM-CSF + Hepatitis B vaccineHepatitis B immune globin + granulocyte-macrophage colony-stimulating factor + HBV vaccine

Targets

HBsAg (Hepatitis B surface antigen)CSF2R (Granulocyte-macrophage colony-stimulating factor receptor)

Beyond the preview

Go deeper on HBIG + GM-CSF + HBV vaccine.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on HBIG + GM-CSF + HBV vaccine.

Explore the full profile